Medical Oncologist
Sorafenib (Nexavar)
When Sorafenib Stops Working: — Resistance and What Comes Next
Hearing that sorafenib has stopped working is frightening. It does not mean treatment has run out. Most people who progress on sorafenib are considered for other options, and those options work through different mechanisms — so resistance to sorafenib does not predict resistance to what comes next.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Resistance is expected — Most cancers eventually find ways around sorafenib. Your oncologist plans for this from the start.
- Other pathways, other drugs — Second-line treatments work differently from sorafenib, so resistance to one does not rule out the others.
- Your cancer type matters — Which next-line options apply depends on whether sorafenib was used for liver, kidney, or thyroid cancer.
- Fitness shapes the choice — How well you tolerated sorafenib, and how you are coping now, guides which option your team recommends.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
When sorafenib stops working, cancer cells have usually found ways to keep growing without relying on the signals sorafenib blocks. This is called acquired resistance. NCCN and ESMO guidance lists several second-line options for the cancers sorafenib treats — the right one depends on your cancer type, your current fitness, and how you tolerated sorafenib.
Why does sorafenib stop working?
Sorafenib works by blocking proteins that cancer cells use to divide and to build their own blood supply. Over time, some cancer cells find alternative routes to achieve the same result without depending on the proteins sorafenib targets.
This is called acquired resistance. The cancer does not change overnight — it gradually favours cells that can survive despite the drug. For most people who do respond to sorafenib, resistance will develop at some point.
A smaller group of people experience primary resistance: the cancer does not respond from the very start. This reflects the tumour's biology rather than the drug failing you.
What do words like 'resistance' and 'progression' actually mean?
- Acquired resistance
- The cancer responded to sorafenib at first but has since developed ways to keep growing despite the drug.
- Primary resistance
- The cancer never responded to sorafenib from the start — a feature of the tumour's biology, not a personal failure.
- Bypass pathway
- An alternative signalling route that cancer cells switch to when the pathway sorafenib blocks is shut down.
- Progression
- Scans show the cancer growing or spreading despite treatment.
- Second-line treatment
- The treatment offered after the first-line treatment has stopped working.
- Performance status
- A measure of how well you are functioning day to day — your team uses it to judge which options are safe to offer.
How does the cancer find a way around sorafenib?
Sorafenib blocks a specific set of signals that tumour cells use to divide and to recruit new blood vessels. Resistance develops when cancer cells switch to alternative routes — called bypass pathways — that achieve the same growth without using the signals sorafenib blocks.
ESMO guidance on sorafenib-treated cancers describes multiple such bypass mechanisms. Which ones become active varies by cancer type and by individual tumour biology, which is why the same drug can work for very different lengths of time in different people.
In some situations your oncologist may suggest repeat testing of your tumour tissue. Tumours can change their characteristics over time, and knowing how yours has changed may help identify which next-line treatment is most likely to help.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What treatment options exist after sorafenib stops working?
The options available depend on which cancer sorafenib was used for, how well you tolerated it, and your current fitness. Your oncologist will consider all three before making a recommendation.
For liver cancer, NCCN and ESMO guidelines list several options including regorafenib, cabozantinib, and ramucirumab, as well as checkpoint immunotherapy agents. Some of these are recommended specifically for people who previously received sorafenib.
For kidney cancer, next-line options include checkpoint immunotherapy, cabozantinib, axitinib, and mTOR inhibitors, among others. For radioactive iodine-refractory thyroid cancer, other targeted agents may be considered.
Not every option suits every person. Your oncologist will identify which options apply to your situation and explain what each one aims to achieve.
What happens when your team confirms that sorafenib has stopped working?
Imaging reviewed
Your scans are reviewed — usually at a multidisciplinary team meeting — to confirm true progression rather than inflammation or a scan artefact.
Fitness assessed
Your oncologist assesses how well you are functioning day to day, since this affects which second-line options are safe to offer.
Sorafenib tolerance reviewed
How you coped with sorafenib matters. Some second-line options are recommended specifically for people who tolerated sorafenib without severe side effects.
Relevant markers checked
Depending on your cancer type, specific tests — such as AFP level in liver cancer — may influence which option is recommended.
Options discussed
Your oncologist explains which options apply to your situation, what each aims to achieve, and what side effects to expect. This is the moment to ask your questions.
Next treatment arranged
Once a plan is agreed, treatment is set up. At CION centres, systemic treatments are delivered as day care.
Questions to ask at your next appointment
- Which second-line option applies specifically to my cancer type?
- Do I need any new tests or a repeat biopsy before starting?
- How quickly should the next treatment begin, and what depends on that timing?
- How do the side effects compare with what I experienced on sorafenib?
- Is there a clinical trial I could be considered for at this stage?
- What will tell us whether the new treatment is working?
Explore 100 more Gastrointestinal & Liver Targeted Medicines topics
Drug Deep Dive: Sorafenib (Nexavar)
- Blood Pressure, Rash and Hair Thinning on Sorafenib
- Diarrhoea on Sorafenib: Controlling It Without Stopping Treatment
- Diet and Nutrition While on Sorafenib
- Drug, Food and Supplement Interactions With Sorafenib
- Fertility, Pregnancy and Contraception on Sorafenib
- Hand-Foot Skin Reaction on Sorafenib: Prevention From Day One
- How Does Sorafenib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sorafenib Take to Work?
- How Long Will You Stay on Sorafenib?
- Sorafenib (Nexavar, Soranib): The Complete Patient Guide
- Sorafenib Myths: Dose Reduction, 'Last Resort' and Generic Quality
- Sorafenib Price in India: Brand, Generic and Monthly Cost
- Sorafenib Side Effects: The Complete List and Timeline
- Sorafenib Success Rate and Survival: An Honest Look at the Numbers
- Sorafenib With Cirrhosis: Why Child-Pugh Status Decides Eligibility
- Sorafenib With TACE and Other Liver-Directed Treatments
- Sorafenib in Elderly Patients and Those With Other Illnesses
- Sorafenib in Liver, Kidney and Thyroid Cancer: Three Different Uses
- Sorafenib vs Lenvatinib for Liver Cancer: Cost, Tolerability and Evidence
- Taking Sorafenib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sorafenib
- When Sorafenib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sorafenib? Liver, Kidney and Radioiodine-Refractory Thyroid Cancer
- Will Insurance or a Government Scheme Pay for Sorafenib?
- Work, Travel and Daily Life on Sorafenib
Drug Deep Dive: Bevacizumab (Avastin)
- Avastin vs Biosimilar Bevacizumab in India: Cost and Safety
- Bevacizumab (Avastin and biosimilars): The Complete Patient Guide
- Bevacizumab Infusion Day: Premedication, Duration and What to Expect
- Bevacizumab Myths: 'It Dissolves Tumours' and Other Misconceptions
- Bevacizumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Bevacizumab Side Effects: The Complete List and Timeline
- Bevacizumab Success Rate and Survival: An Honest Look at the Numbers
- Bevacizumab With Chemotherapy: Which Combinations and Why
- Bevacizumab in Elderly Patients and Those With Other Illnesses
- Bevacizumab in Eye Disease vs Cancer: Same Drug, Very Different Dose
- Bleeding, Bowel Perforation and Wound Healing Risks on Bevacizumab
- Diet and Nutrition While on Bevacizumab
- Drug, Food and Supplement Interactions With Bevacizumab
- Fertility, Pregnancy and Contraception on Bevacizumab
- High Blood Pressure on Bevacizumab: Monitoring and Treatment
- How Does Bevacizumab Work? The Anti-VEGF Angiogenesis Inhibitor Explained
- How Long Does Bevacizumab Take to Work?
- How Long Will You Stay on Bevacizumab?
- Protein in Your Urine on Bevacizumab: What the Report Means
- Surgery While on Bevacizumab: The 28-Day Rule
- Tests and Monitoring While You Are on Bevacizumab
- When Bevacizumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Bevacizumab? Colorectal, Lung, Ovarian, Cervical and Brain Cancer
- Will Insurance or a Government Scheme Pay for Bevacizumab?
- Work, Travel and Daily Life on Bevacizumab
Drug Deep Dive: Cetuximab (Erbitux)
- Cetuximab (Erbitux): The Complete Patient Guide
- Cetuximab Infusion Day: Premedication, Duration and What to Expect
- Cetuximab Infusion Reactions: Why the First Dose Is Given Slowly
- Cetuximab Myths: 'The Worse the Rash, the Better' and Other Half-Truths
- Cetuximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Cetuximab Side Effects: The Complete List and Timeline
- Cetuximab Success Rate and Survival: An Honest Look at the Numbers
- Cetuximab With FOLFIRI, FOLFOX and Radiation
- Cetuximab in Colorectal vs Head and Neck Cancer: Different Roles
- Cetuximab in Elderly Patients and Those With Other Illnesses
- Cetuximab vs Bevacizumab in Colorectal Cancer: Which and When
- Diet and Nutrition While on Cetuximab
- Drug, Food and Supplement Interactions With Cetuximab
- Fertility, Pregnancy and Contraception on Cetuximab
- How Does Cetuximab Work? The Anti-EGFR Monoclonal Antibody Explained
- How Long Does Cetuximab Take to Work?
- How Long Will You Stay on Cetuximab?
- Low Magnesium on Cetuximab: Cramps, Fatigue and Monthly Testing
- Tests and Monitoring While You Are on Cetuximab
- The Cetuximab Rash: Severity, Treatment and Why It Predicts Response
- When Cetuximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Cetuximab? RAS Wild-Type Colorectal Cancer and Head and Neck Cancer
- Why Cetuximab Only Works in RAS Wild-Type, Left-Sided Tumours
- Will Insurance or a Government Scheme Pay for Cetuximab?
- Work, Travel and Daily Life on Cetuximab
Drug Deep Dive: Lenvatinib (Lenvima)
- Blood Pressure Spikes on Lenvatinib: The Critical First Two Weeks
- Diarrhoea, Appetite Loss and Rapid Weight Drop on Lenvatinib
- Diet and Nutrition While on Lenvatinib
- Dose Reductions on Lenvatinib: Why Most Patients Need One
- Drug, Food and Supplement Interactions With Lenvatinib
- Fertility, Pregnancy and Contraception on Lenvatinib
- Hand-Foot Skin Reaction on Lenvatinib: Prevention and Relief
- How Does Lenvatinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Lenvatinib Take to Work?
- How Long Will You Stay on Lenvatinib?
- Lenvatinib (Lenvima, Lenvanix): The Complete Patient Guide
- Lenvatinib Myths: Side Effects, Dose Cuts and 'Giving Up'
- Lenvatinib Price in India: Brand, Generic and Monthly Cost
- Lenvatinib Side Effects: The Complete List and Timeline
- Lenvatinib Success Rate and Survival: An Honest Look at the Numbers
- Lenvatinib With Immunotherapy: The Combination Explained
- Lenvatinib for Radioactive-Iodine-Refractory Thyroid Cancer
- Lenvatinib in Elderly Patients and Those With Other Illnesses
- Lenvatinib vs Sorafenib for Liver Cancer: Which Comes First?
- Taking Lenvatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Lenvatinib
- When Lenvatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Lenvatinib? Liver, Thyroid, Kidney and Endometrial Cancer
- Will Insurance or a Government Scheme Pay for Lenvatinib?
- Work, Travel and Daily Life on Lenvatinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How does my oncologist know sorafenib has stopped working?
Progression is confirmed by imaging — usually a CT or MRI scan — showing the tumour has grown or spread since your last scan. Blood markers such as AFP in liver cancer are considered alongside the imaging. Most teams review the findings at a multidisciplinary meeting before deciding to change treatment. A single ambiguous result rarely triggers an immediate switch; your oncologist is looking for a clear pattern, not a one-off reading.
Does resistance to sorafenib mean other treatments will not work?
No. Sorafenib resistance is specific to the pathway it targets. Second-line treatments work through different mechanisms — some block other growth signals, others activate the immune system against the cancer. NCCN and ESMO guidance lists multiple options after sorafenib for precisely this reason. A proportion of patients achieve disease control on second-line treatment, and resistance to sorafenib does not predict resistance to a drug that works differently.
Is regorafenib always the next step after sorafenib in liver cancer?
Not automatically. Regorafenib is a NCCN and ESMO-listed option after sorafenib in hepatocellular carcinoma, and it was studied specifically in patients who previously received and tolerated sorafenib. But cabozantinib, ramucirumab, and checkpoint immunotherapy agents are also listed options. Your oncologist will match the choice to your specific results, your side effect history on sorafenib, and your current fitness — the conversation should cover all relevant options, not just one.
Can sorafenib ever be restarted after it stops working?
Restarting sorafenib after progression is not part of standard NCCN or ESMO treatment sequences. Cancer cells that grew through sorafenib have already adapted to survive it, so restarting is unlikely to produce a meaningful response. Treatment decisions at this stage are highly individual, and your oncologist will discuss any option they consider relevant to your specific situation — but a return to sorafenib is not typically among them.
How long does it take to start the next treatment after progression is confirmed?
There is no clinical reason to delay once progression is confirmed and a plan is agreed. In practice, the timeline depends on whether any new tests are needed first — a repeat biopsy, for instance, takes time to arrange and process. Most oncology teams aim to keep the gap between progression and starting the next treatment as short as possible. If you are concerned about delay, ask your team directly what their intended timeline is and what is waiting before treatment can begin.
What if I am not well enough for another active treatment?
This is a direct and important question, and your oncologist will give you an honest answer. Some second-line options are suitable for people with reduced fitness; others are not. If active treatment is not appropriate at a given point, care does not stop — managing symptoms and supporting your quality of life remain active goals. Ask your team to explain concretely what that looks like for your situation, including which symptoms can be addressed and how.